/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Nuveen Closed-End Funds Declare Distributions
Distributions Highlight Nuveen’s Broad Range of Strategies for
Income-Seeking Investors
- Regular Monthly Tax-Exempt and Taxable Fund Distributions
- JQC Declares Monthly Capital Return Plan Distribution
- Three Funds Declare Monthly Cash-Flow Based Distributions
NEW YORK–(BUSINESS WIRE)–Several Nuveen closed-end funds have declared distributions. These funds
represent investment strategies for investors seeking diversified
sources of cash flow to prepare for and sustain their income needs. For
further information regarding fund distributions including earnings,
undistributed net investment income, and notices please visit http://www.nuveen.com/cef.
The following dates apply to today’s monthly distribution declarations
for the following tax-exempt and taxable closed-end funds:
Record Date | May 15, 2019 | |||
Ex-Dividend Date | May 14, 2019 | |||
Payable Date | June 3, 2019 | |||
Monthly Tax-Exempt Municipal Distributions
Monthly distributions from Nuveen’s municipal bond closed-end funds are
generally exempt from regular Federal income taxes, and monthly
distributions of single-state municipal funds are also generally exempt
from state and, in some cases, local income taxes for in-state
residents. Unless otherwise stated in the funds’ objectives, monthly
distributions of the municipal funds may be subject to the Federal
Alternative Minimum Tax for some shareholders.
Monthly Tax-Free Distribution Per Share | ||||||||
Change From | ||||||||
Ticker |
Exchange |
Fund Name |
Amount | Previous Month | ||||
National |
||||||||
NXP | NYSE | Nuveen Select Tax-Free Income Portfolio | $.0455 | – | ||||
NXQ | NYSE | Nuveen Select Tax-Free Income Portfolio 2 | $.0420 | – | ||||
NXR | NYSE | Nuveen Select Tax-Free Income Portfolio 3 | $.0435 | – | ||||
NUV | NYSE | Nuveen Municipal Value Fund, Inc. | $.0310 | – | ||||
NUW | NYSE | Nuveen AMT-Free Municipal Value Fund | $.0560 | – | ||||
NMI | NYSE | Nuveen Municipal Income Fund, Inc. | $.0360 | – | ||||
NIM | NYSE | Nuveen Select Maturities Municipal Fund | $.0265 | – | ||||
NZF | NYSE | Nuveen Municipal Credit Income Fund | $.0660 | – | ||||
NVG | NYSE | Nuveen AMT-Free Municipal Credit Income Fund | $.0655 | – | ||||
NMZ | NYSE | Nuveen Municipal High Income Opportunity Fund | $.0595 | – | ||||
NEV | NYSE | Nuveen Enhanced Municipal Value Fund | $.0565 | – | ||||
NID | NYSE | Nuveen Intermediate Duration Municipal Term Fund | $.0425 | – | ||||
NIQ | NYSE | Nuveen Intermediate Duration Quality Municipal Term Fund | $.0315 | – | ||||
NHA | NYSE | Nuveen Municipal 2021 Target Term Fund | $.0150 | – | ||||
NEA | NYSE | Nuveen AMT-Free Quality Municipal Income Fund | $.0535 | – | ||||
NAD | NYSE | Nuveen Quality Municipal Income Fund | $.0535 | – | ||||
California |
||||||||
NAC | NYSE | Nuveen California Quality Municipal Income Fund | $.0555 | – | ||||
NKX | NYSE | Nuveen California AMT-Free Quality Municipal Income Fund | $.0515 | – | ||||
NCA | NYSE | Nuveen California Municipal Value Fund, Inc. | $.0285 | – | ||||
NXC | NYSE | Nuveen California Select Tax-Free Income Portfolio | $.0410 | – | ||||
NCB | NYSE | Nuveen California Municipal Value Fund 2 | $.0540 | – | ||||
New York |
||||||||
NRK | NYSE | Nuveen New York AMT-Free Quality Municipal Income Fund | $.0450 | – | ||||
NAN | NYSE | Nuveen New York Quality Municipal Income Fund | $.0480 | – | ||||
NXN | NYSE | Nuveen New York Select Tax-Free Income Portfolio | $.0395 | – | ||||
NNY | NYSE | Nuveen New York Municipal Value Fund, Inc. | $.0300 | – | ||||
NYV | NYSE | Nuveen New York Municipal Value Fund 2 | $.0425 | – | ||||
Other State Funds |
||||||||
NAZ | NYSE | Nuveen Arizona Quality Municipal Income Fund | $.0415 | – | ||||
NTC | NYSE | Nuveen Connecticut Quality Municipal Income Fund | $.0410 | – | ||||
NKG | NYSE | Nuveen Georgia Quality Municipal Income Fund | $.0370 | – | ||||
NMT | NYSE | Nuveen Massachusetts Quality Municipal Income Fund | $.0410 | – | ||||
NMY | NYSE | Nuveen Maryland Quality Municipal Income Fund | $.0440 | – | ||||
NUM | NYSE | Nuveen Michigan Quality Municipal Income Fund | $.0445 | – | ||||
NMS | NYSE | Nuveen Minnesota Quality Municipal Income Fund | $.0490 | – | ||||
NOM | NYSE | Nuveen Missouri Quality Municipal Income Fund | $.0430 | – | ||||
NNC | NYSE | Nuveen North Carolina Quality Municipal Income Fund | $.0390 | – | ||||
NXJ | NYSE | Nuveen New Jersey Quality Municipal Income Fund | $.0545 | – | ||||
NJV | NYSE | Nuveen New Jersey Municipal Value Fund | $.0450 | – | ||||
NUO | NYSE | Nuveen Ohio Quality Municipal Income Fund | $.0455 | – | ||||
NQP | NYSE | Nuveen Pennsylvania Quality Municipal Income Fund | $.0505 | – | ||||
NPN | NYSE | Nuveen Pennsylvania Municipal Value Fund | $.0405 | – | ||||
NTX | NYSE | Nuveen Texas Quality Municipal Income Fund | $.0445 | – | ||||
NPV | NYSE | Nuveen Virginia Quality Municipal Income Fund | $.0435 | – | ||||
Monthly Taxable Distributions
Monthly Distribution Per Share | ||||||||
Change From | ||||||||
Ticker |
Exchange |
Fund Name |
Amount | Previous Month | ||||
Preferred and Income Securities |
||||||||
JPC | NYSE | Nuveen Preferred & Income Opportunities Fund | $.0610 | – | ||||
JPI | NYSE | Nuveen Preferred and Income Term Fund | $.1355 | – | ||||
JPS | NYSE | Nuveen Preferred & Income Securities Fund | $.0560 | – | ||||
JPT | NYSE | Nuveen Preferred and Income 2022 Term Fund | $.1185 | – | ||||
Floating Rate |
||||||||
NSL | NYSE | Nuveen Senior Income Fund | $.0375 | – | ||||
JFR | NYSE | Nuveen Floating Rate Income Fund | $.0615 | – | ||||
JRO | NYSE | Nuveen Floating Rate Income Opportunity Fund | $.0625 | – | ||||
JSD | NYSE | Nuveen Short Duration Credit Opportunities Fund | $.1035 | – | ||||
Mortgage-Backed Securities |
||||||||
JMM | NYSE | Nuveen Multi-Market Income Fund | $.0300 | – | ||||
Taxable Municipals |
||||||||
NBB | NYSE | Nuveen Taxable Municipal Income Fund | $.1030 | – | ||||
Emerging Markets Debt |
||||||||
JEMD | NYSE | Nuveen Emerging Markets Debt 2022 Target Term Fund | $.0375 | – | ||||
Global High Yield Debt |
||||||||
JGH | NYSE | Nuveen Global High Income Fund | $.1020 | – | ||||
Corporate High Yield Debt |
||||||||
JHY | NYSE | Nuveen High Income 2020 Target Term Fund | $.0350 | – | ||||
JHD | NYSE | Nuveen High Income December 2019 Target Term Fund | $.0325 | – | ||||
JHB | NYSE | Nuveen High Income November 2021 Target Term Fund | $.0415 | – | ||||
JCO | NYSE | Nuveen Credit Opportunities 2022 Target Term Fund | $.0470 | – | ||||
JHAA | NYSE | Nuveen High Income 2023 Target Term Fund | $.0520 | – | ||||
Monthly Capital Return Plan Policy Distribution
JQC has adopted a capital return plan through which the fund will return
to shareholders 20 percent of the fund’s common assets, over a period of
three years ending on December 31, 2021, through supplemental amounts
included in the fund’s regular monthly distribution. Distribution
sources will include net investment income and return of capital and may
include realized gains. The fund will provide a notice of the best
estimate of its distribution sources at that time which may be
viewed at: www.nuveen.com/CEFdistributions.
These estimates may not match the final tax characterization (for the
full year’s distributions) contained in shareholders’ 1099-DIV forms
after the end of the year.
You should not draw any conclusions about a fund’s past or future
investment performance from its current distribution rate.
The following dates apply to today’s monthly capital return distribution
declaration for the following closed-end fund:
Record Date | May 15, 2019 | ||||
Ex-Dividend Date | May 14, 2019 | ||||
Payable Date | June 3, 2019 | ||||
Monthly Distribution Per Share | ||||||||
Change From | ||||||||
Ticker |
Exchange |
Fund Name |
Amount | Previous Month | ||||
Floating Rate |
||||||||
JQC |
NYSE |
Nuveen Credit Strategies Income Fund |
$.1035 |
– |
||||
Monthly Cash-Flow Based Distributions
Each of the three taxable funds listed immediately below have adopted a
cash-flow based distribution program. Historical distribution sources
have included net investment income, realized gains and return of
capital. If a distribution includes anything other than net investment
income, the fund provides a notice of the best estimate of its
distribution sources at the time of payment which may be viewed at: www.nuveen.com/CEFdistributions.
These estimates may not match the final tax characterization (for the
full year’s distributions) contained in shareholders’ 1099-DIV forms
after the end of the year.
You should not draw any conclusions about a fund’s past or future
investment performance from its current distribution rate.
The following dates apply to today’s monthly cash-flow based
distribution declarations for the following closed-end funds:
Record Date | May 15, 2019 | |||
Ex-Dividend Date | May 14, 2019 | |||
Payable Date | June 3, 2019 |
Monthly Distribution Per Share | ||||||||
Change From | ||||||||
Ticker |
Exchange |
Fund Name |
Amount | Previous Month | ||||
Mortgage-Backed Securities |
||||||||
JLS | NYSE | Nuveen Mortgage Opportunity Term Fund | $.1135 | – | ||||
JMT | NYSE | Nuveen Mortgage Opportunity Term Fund 2 | $.1125 | – | ||||
Real Assets |
||||||||
JRI | NYSE | Nuveen Real Asset Income and Growth Fund | $.1060 | – | ||||
The information contained on the Nuveen website is not a part of this
press release.
Nuveen, the investment manager of TIAA, offers a comprehensive range of
outcome-focused investment solutions designed to secure the long-term
financial goals of institutional and individual investors. Nuveen has
$989 billion in assets under management as of 3/31/19 and operations in
16 countries. Its affiliates offer deep expertise across a comprehensive
range of traditional and alternative investments through a wide array of
vehicles and customized strategies. For more information, please visit www.nuveen.com.
The information contained on the Nuveen website is not a part of this
press release. Nuveen Securities, LLC, member FINRA and SIPC.
* Nuveen does not provide tax advice; consult a professional tax advisor
regarding your specific tax situation. Income may be subject to state
and local taxes, as well as the federal alternative minimum tax.
837026-INV-O-05/21
Contacts
Name Kristyna Munoz
Phone 254-644-1615
Email [email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
SCHWAZZE
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
DENVER, April 29, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), will host a conference call on Wednesday, May 15, 2024 at 5:00 p.m. Eastern time to discuss its financial and operational results for the first quarter ended March 31, 2024. The Company’s results will be reported in a press release prior to the call.
The Schwazze management team will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].
Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call
The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.
Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit http://www.schwazze.com/.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/schwazze-sets-first-quarter-2024-conference-call-for-may-15-2024-at-500-pm-et-302130423.html
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Innocan
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use
HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].
Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.
Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.“
Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:
“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market
[2] https://www.cdc.gov/opioids/data/index.html
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html
-
transfer2 weeks ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis2 weeks ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®2 weeks ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis7 days ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care